Kevin D. Bunker Ph.D.
Net Worth
Last updated:
What is Kevin D. Bunker Ph.D. net worth?
The estimated net worth of Dr. Kevin D. Bunker Ph.D. is at least $26,825,701 as of 4 Oct 2023. He owns shares worth $1,365,952 as insider, has earned $21,962,249 from insider trading and has received compensation worth at least $3,497,500 in Zentalis Pharmaceuticals, Inc..
What is the salary of Kevin D. Bunker Ph.D.?
Dr. Kevin D. Bunker Ph.D. salary is $699,500 per year as Chief Operating Officer in Zentalis Pharmaceuticals, Inc..
How old is Kevin D. Bunker Ph.D.?
Dr. Kevin D. Bunker Ph.D. is 52 years old, born in 1973.
What stocks does Kevin D. Bunker Ph.D. currently own?
As insider, Dr. Kevin D. Bunker Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | Chief Operating Officer | 859,089 | $1.59 | $1,365,952 |
What does Zentalis Pharmaceuticals, Inc. do?
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Kevin D. Bunker Ph.D. insider trading
Zentalis Pharmaceuticals, Inc.
Dr. Kevin D. Bunker Ph.D. has made 74 insider trades between 2020-2023, according to the Form 4 filled with the SEC. Most recently he sold 983 units of ZNTL stock worth $19,572 on 4 Oct 2023.
The largest trade he's ever made was exercising 80,000 units of ZNTL stock on 26 May 2023. As of 4 Oct 2023 he still owns at least 859,089 units of ZNTL stock.
Zentalis Pharmaceuticals key executives
Zentalis Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Anthony Y. Sun M.D. (53) Pres, Chief Executive Officer & Executive Chairman
- Dr. Kevin D. Bunker Ph.D. (52) Chief Operating Officer
- Mr. Cam S. Gallagher M.B.A. (55) Sec. & Director
- Ms. Alexis M. Pinto J.D. (58) Chief Legal Officer & Sec.